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Background: Rhinovirus infections do not only cause common colds, but may also trigger severe exacerbations
of asthma and chronic obstructive pulmonary disease (COPD). Even though rhinoviruses have been the focus of
extensive drug development efforts in the past, an anti-rhinoviral drug still has to make it to the market. In the past,
the viral capsid protein VP1 has been shown to be an important target for the development of antiviral molecules.
Furthermore, many different chemical scaffolds appear to possess the properties that are required to inhibit virus
replication by this mechanism of action. I-6602, an analogue of the rhinovirus inhibitor pirodavir, was previously
identified as a potent inhibitor of rhinovirus infection. Here, we describe the antiviral activity of its analogue ca603,
a molecule with a modified linker structure, and corroborate its mechanism of action as a capsid binder.
Findings: The molecule ca603 shows antiviral activity against a panel of rhino-and enteroviruses. Cross-resistance is
observed against viruses with mutations that render them resistant to the inhibitory effect of the capsid binder
pleconaril and thermostability assays demonstrate that the compound binds and stabilizes the viral capsid. Binding
of the molecule to the VP1 protein is corroborated by in silico modeling.
Conclusions: It is confirmed that ca603 inhibits rhinovirus replication by interaction with the VP1 protein and, by this,
allows to further expand the chemical diversity of capsid-binding molecules.Body of text
The genus Enterovirus comprises several human patho-
gens with a substantial clinical impact on society like
poliovirus (PV), rhinoviruses (HRV) and enterovirus 71
(EV71) [1]. Rhinoviruses cause common colds in healthy
people but may trigger exacerbations in patients with
asthma and COPD [2, 3]. Vaccination against rhinovirus
infection is not yet feasible due to the large number of
serotypes. Treatment with small-molecule inhibitors
therefore seems to be the best possible option to lower
the burden of this disease. To date, the rhinoviral capsid
and protease are the best characterized antiviral targets.
However, a drug has still to be approved for clinical
use [1]. In the past, several early-stage rhinovirus* Correspondence: johan.neyts@rega.kuleuven.be
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Pleconaril, pirodavir and vapendavir are the most exten-
sively studied capsid binders (Fig. 1). In 2002, the New
Drug Application for pleconaril (Schering-Plough) as drug
against the common cold was rejected by the FDA, mainly
because of safety reasons [4, 5]. Pirodavir (Janssen Phar-
maceutica) inhibits in vitro the replication of both HRV-
A,–B and, to a lesser extend, that of other enteroviruses
[6]. Prophylactic treatment with pirodavir reduced the fre-
quency of experimental rhinovirus infections and subse-
quent clinical colds only when the drug was administered
intranasally six times a day [7]. Oral delivery of the ester-
derivate pirodavir is not feasible given the fact that it rap-
idly hydrolyses to an inactive acid. No reduction of clinical
symptoms was observed in the subsequent therapeutic
trial with experimental rhinovirus infection. Although piro-
davir treatment of naturally acquired rhinovirus infections
significantly reduced virus shedding during the treatment
period, no positive outcome on the clinical signs andrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Structural formulae of (a) ca603, (b) pirodavir, and (c) pleconaril
Table 1 Activity of ca603 and pleconaril against representative
viruses from HRV-A and B; and EV-A,-B and-C
Virus strain EC50 (ca603) (μM) EC50 (pleconaril) (μM)
HRV-A HRV02 >313 0.2 ± 0.1*
HRV09 8.9 ± 4.2* 0.2 ± 0.1*
HRV29 1.7 ± 0.04* 0.1 ± 0.1*
HRV63 >157 0.1 ± 0.1*
HRV85 3.7 ± 2.0* 0.1 ± 0.1*
HRV89 0.9 ± 0.8* 0.7 ± 0.3*
HRV-B HRV14 0.10 ± 0.03* 0.3 ± 0.2*
HRV42 8.2 ± 4.7 >26
HRV70 15 ± 8* 4 ± 3.6
HRV86 0.01 ± 0.003* 0.1 ± 0.1*
EV-A EV71 74 ± 5 >52
EV-B CVB3 >313 >131
EV-B ECHO11 2.5 ± 1.6 1.7 ± 0.4
EV-C PV1 25 ± 7 >131
Antiviral activity was determined in a CPE reduction assay with MTS read-out.
EC50 = median 50 % effective concentration ±MAD from dose response curves
set up from ≥ four experiments of which at least two independent. * = 100 %
inhibition of virus-induced cytopathic effect can be achieved with this
compound (as determined by microscopic inspection). CC50 HeLa = 153 ± 19 μM;
CC50 BGM = 171 ± 16 μM; CC50 RD= 221 ± 28 µM
Fig. 2 Compound ca603 (black) inhibits HRV14 replication only
when added at an early stage and behaves similar to pleconaril
(grey). Compounds were added prior to, at the time of, or after viral
infection at indicated time points and viral RNA was quantified 8 h
pi. Intracellular viral RNA load was expressed as equivalents of 50 %
tissue infective dose/mL (log (TCID50/mL) eq.) (mean ± STD from two
independent assays). Insert: Intracellular viral HRV14 RNA increased from
baseline input (0 h) till 8 h post-infection (one full virus replication cycle)
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trials, pirodavir treatment was associated with an unpleasant
taste and the more frequent presence of blood in the nasal
mucus. Vapendavir (Biota Holdings), a benzisoxazole ana-
logue of pirodavir, is currently in clinical development for
the treatment of rhinovirus-induced asthma exacerbations
[9]. In the past, we explored the antiviral activity of a panel
of pirodavir analogues with modifications of the central
hydrocarbon chain [10, 11]. Here, we report on the particu-
lar characteristics of the antiviral activity and mode of action
of a novel and the until now most potent and least toxic
analogue in this series (Fig. 1). Compound ca603 has been
designed based on the structure of I-6602 and was synthe-
sized at ASM Company (Burgwedel, Germany).
The antiviral activity of ca603 was assessed in a multi-
cycle, virus-cell-based cytopathic effect (CPE) reduction
assay in HeLa cells [12]. The compound proved to be
active against HRV strains from both the HRV-A (HRV09,
HRV29, HRV85 and HRV89) and HRV-B group (HRV14,
HRV70 and HRV86) (Table 1) with a 50 % effective con-
centrations (EC50’s) ranging from 0.01 μM to 15 μM.
Although ca603 exerted in vitro antiviral activity against
EV71, PV1 and echovirus 11 (ECHO11), the compound
was not able to induce complete protection against virus-
induced CPE at non-toxic concentrations (Table 1).
Early-stage inhibitors like pleconaril and pirodavir are
only able to prevent virus replication when added prior
to, or at the time of infection in a time-of-drug additionassay. Akin to pleconaril, ca603 lost its inhibitory activity
when added after infection, indicating that ca603 acts, as
expected, at an early stage in the rhinovirus replication
cycle (Fig. 2).
Next, the antiviral potency of ca603 was assessed on the
replication of two earlier-reported pleconaril-resistant
Table 2 Reverse-engineered HRV14 virus mutants that carry a mutation in VP1 are less susceptible to the antiviral effect of ca603
and pleconaril. Sensitivity to the protease-inhibitor rupintrivir remained unchanged
HRV14IC ca603 Pleconaril Rupintrivir
EC50 (μM) RR EC50 (μM) RR EC50 (μM) RR
Wild-type 0.014 ± 0.001 / 0.057 ± 0.004 / 0.0058 ± 0.0002 /
VP1_A150V 0.15 ± .0.02* 10 2.3 ± 0.1* 40 0.010 ± 0.001* 2
VP1_A150V_E276K 0.16 ± 0.02* 12 1.6 ± 0.2** 28 0.005 ± 0.0002 1
Activity was determined in a CPE reduction assay with MTS read-out. EC50 = median 50 % effective concentration ±MAD. Data are in duplicate from three
independent assays. RR = relative resistance (EC50 of mutated strain / EC50 of wild-type). *p < 0.0001, **p < 0.001
Fig. 3 Effect of ca603 and pleconaril on heat-inactivation of HRV14.
a HRV14ICwild-type and HRV14IC VP1_A150V_E276K are equally
inactivated by increasing temperatures. b Both ca603 and pleconaril
were able to rescue wild-type virus from heat-inactivation. c The mutant
VP1_A15V_E276K shows reduced protection from heat-inactivation in
the presence of ca603 and pleconaril. Data are in duplicate from two
independent assays (mean ± STD)
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site-directed mutagenesis (Quikchange-Stratagene, primer
sequences available on request) in a HRV14 infectious
clone (kindly provided by D. Blaas, University of Vienna,
Austria). Viruses derived from this infectious clone (IC)
are designated as HRV14IC. The single mutant HRV14IC
VP1_A150V proved to be 10-and 40-fold less sensitive
to ca603 and pleconaril, respectively (Table 2). Both
ca603 and pleconaril proved also markely less active
(12-and 28-fold, respectively) against the double mutant
HRV14ICVP1_A150V_E276K.
Rhinoviruses are sensitive to thermal stress. However,
interaction with a capsid binder can stabilize the virion
and increase the temperature at which heat inactivation
occurs. We assessed the effect of ca603 on two HRV14IC
strains in a thermostability assay (Fig. 3). HRV14IC wild-
type or HRV14IC VP1_A150V_E276K were incubated
with a fixed concentration of ca603 (1 μM) or pleconaril
(10 μM) for 15 min at 37 °C, 2 min at temperatures
ranging from 37-57 °C (Lightcycler 96, Roche), followed
by a rapid cool down to 4 °C. Infectious viral loads
were subsequently quantified by end-point titration.
Both HRV14IC wild-type and HRV14IC VP1_A150V_E276K
were equally sensitive to heat-inactivation (Fig. 3a):
gradual loss of infectivity is observed by increasing the
temperature to 57 °C. In the presence of ca603 and pleco-
naril, heat-inactivation of HRV14IC wild-type shifted to
higher temperatures, suggesting that both compounds
stabilize the viral capsid and protect the virus from heat
degradation (Fig. 3b). Both compounds were not able to
preserve the infectivity of HRV14IC VP1_A150V_E276K
to the same extent, indicating loss of interaction with
either compound (Fig. 3c). Some residual protection was
still observed, which is in agreement with the fact that the
reverse-engineered pleconaril-resistant HRV strain is
only partially resistant to the antiviral activity of the
compounds.
Sequence alignment of the VP1 residues reported to
constitute the hydrophobic pocket within the capsid
were constructed with the use of CLC sequence viewer
(Qiagen). For the HRV-B strains in the test panel, no
satisfying explanation could be derived from this
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against HRV42 and HRV70 compared to the potent activ-
ity (<2 μM) against HRV14 and HRV86 (Additional file 1:
Figure S1). Also for the panel of HRV-A strains, no pat-
tern of residues in the hydrophobic pocket could explain
the difference in activity (from none against HRV2 and
HRV63, moderate against HRV9 and HRV 85, to potent
activity against HRV29 and HRV 89) (Additional file 2:
Figure S2). The full alignment of HRV-A VP1 proteins re-
vealed an alanine on position 176 (HRV02, FG loop) for
the naturally compound-resistant strains, while a serine or
threonine was detected for the strains against which mod-
erate activity was observed, and a proline in the most sus-
ceptible strains (Fig. 4).
The cross-resistance and thermostabilizing studies
indicate that the antiviral effect of ca603 is due to aFig. 4 Sequence alignment of the HRV-A VP1 residues. Alignment was conpleconaril-like mechanism of action, i.e. acting as a cap-
sid binder. The pleconaril/HRV14 capsid protein cocrys-
tal structure (PDB id 1NCQ) [13] was used to study the
binding mode of ca603. The Plants-proposed [14] ca603
docking pose well resembled the binding mode that was
reported for pleconaril with the two derivatives sharing
many key interactions. In particular for ca603, we ob-
served that 1) the oxazole ring was stabilized by hy-
drophobic interactions with Y197 and L106; 2) the alkyl
chain formed extensive van der Waals contacts with
I104, V188 and V191; 3) the aryl ring established π-
interactions with Y152 and Y128; and 4) the ethoxycar-
bonyl function made hydrophobic interactions mainly
with F186 and P174 (Fig. 5). For a better understanding of
how the observed mutations induce resistance, the inter-
action of the compound was also investigated in thestructed with CLC sequence viewer (Qiagen)
Fig. 5 Plants-proposed binding mode for pleconaril (cyan) and ca603 (magenta) in the HRV14 VP1. Residues involved in direct interactions are
depicted as white sticks
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introduced. Replacing the alanine at the bottom tip of the
cleft with the bulkier valine narrowed the binding pocket,
which causes a slight shift in binding mode. It should be
noted that this shift did not disrupt the key binding interac-
tions that were observed for wild-type HRV14 (Additional
file 3: Figure S3). The modelling results therefore corrobor-
ate the biological results (i.e. a decrease in sensitivity but no
full resistance) and validate the observed correlation be-
tween primary amino acid sequence of the binding site and
the observed anti-HRV activity against wild-type and
compound-resistant HRV14 variants.
Additional docking studies were carried out with the
VP1 of HRV42, a virus serotype featuring the Y152F and
V191L mutations that have been associated with re-
sistance to pleconaril [15]. It was reported that the re-
placement of valine with the bulkier leucine narrowed
the binding cleft with consequent negative steric effects
[15]. Among the studied compounds, the pleconaril
binding mode was markedly affected by the bulkier
dimethyphenyl group close to position 191 (RMSD >2).
On the contrary, the binding mode of ca603 seemed to be
only weakly affected due to the smaller size of the unsub-
stituted phenyl ring near position 191, while all other
interactions were retained, which is reflected in the anti-
HRV42 activity of ca603 (Additional file 4: Figure S4).Additional files
Additional file 1: Figure S1. Sequence alignment of the HRV-B VP1
residues ligning the hydrophobic pocket (constructed with CLC sequence
viewer (Qiagen)).
Additional file 2: Figure S2. Sequence alignments of the HRV-A VP1
residues ligning the hydrophobic pocket (constructed with CLC sequence
viewer (Qiagen)).Additional file 3: Figure S3. Top: Plants-proposed binding mode of
ca603 in the HRV14 VP1_A150V (orange) and HRV14 wild-type (magenta)
binding site. Bottom: Plants-proposed binding mode of pleconaril in the
HRV14 VP1_A150V (orange) and HRV14 wild-type (cyan) binding site.
Residues involved in direct interactions are depicted as white sticks,
mutated residues are reported as pink sticks.
Additional file 4: Figure S4. Plants-proposed binding mode of ca603
(yellow) in the HRV-B42 binding site; ca603 binding mode (magenta) in
the HRV-B14 binding site is also shown. Residues involved in direct
interactions are depicted as white sticks, mutated residues are reported
as pink sticks.
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